01498.HK
PuraPharm Corporation Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · HK
HKD 0.23
−0.86%Year over year
Reported trailing growth
- Revenue
- -6.7%
- EBITDA
- +46.1%
- EBIT
- +65.0%
- EPS
- +41.7%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -9.1%
- EBITDA
- -22.3%
- EBIT
- -1.9%
- Net income
- +0.6%
- EPS
- +6.2%
- Free cash flow
- -15.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026